Tags Archive Navigation
icon
-
Media ReleaseNovartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
-
StoryDrug delivery, service delivery, and the future of cancer care
-
StoryListening to the CML patient community
-
Media ReleaseNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
-
StoryFacing the fear of breast cancer recurrence
-
Media ReleaseNovartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
-
Landing PageMy Cancer. My Words.
-
Interior PageOncology
-
Interior PageRadioligand therapy: delivering now, building for the future
-
Media ReleaseNovartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
-
Media ReleaseNovartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
-
Media ReleaseNovartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 14
- › Next page